Login to Your Account



Fun With Financials

VC Investments in Biotech Dip 12%, But Deal Size Doubles

By Cynthia Robbins-Roth


Wednesday, October 5, 2011
The steady drip, drip, drip of excess stomach acid experienced by biotech venture capitalists, institutional investors and employees is sadly in sync with the steady drip, drip, drip of capital away from the sector.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription